Navigation Links
Rigel to Present at UBS Global Life Sciences Conference
Date:9/17/2012

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the UBS Global Life Sciences Conference in New York City on Thursday, September 20th at 4:30 p.m. ET.

To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 clinical trials; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders.

Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
2. Rigel Announces Second Quarter 2012 Financial Results
3. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
4. Rigel Announces First Quarter 2012 Financial Results
5. Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
6. HeartWare Presentation at the UBS Global Life Sciences Conference to be Webcast
7. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
8. Depomed To Present At UBS Global Life Sciences Conference
9. Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
10. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
11. Abaxis, Inc. to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... -- Kalorama Information has noted five news developments in ... industry.  This month the FDA granted a CLIA waiver to ... market has reached $18.4 billion in sales and continues ... battle and the acquisition by Abbott is still in ... chemistry analyzer and researchers evaluated fetal fibronectin screening for ...
(Date:3/22/2017)... , March 22, 2017 NetworkNewsWire Editorial ... ... given differing statements by White House officials. Federal laws are ... marijuana for medical and/or recreational use, and businesses like SinglePoint, ... Inc. (NASDAQ: CRBP), Medical Marijuana, Inc. (OTC: MJNA), Cannabis Science, ...
(Date:3/22/2017)... March 22, 2017  Based on its recent ... & Sullivan recognizes GE Healthcare with the 2016 ... Award. GE Healthcare,s strategy of innovating and expanding ... allowed it to effectively compete in a mature, ... In addition to aiding patient and clinician workflows, ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... Influence Health, the ... solutions have enabled Children’s Hospital of The King’s Daughters (CHKD) to achieve a ... value of a digital marketing approach, the 206-bed pediatric teaching hospital in Norfolk, ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Burke Medical Research ... translate advances in basic neuroscience at the BMRI labs into new and improved ... improve movement, vision, and cognition impaired by stroke, traumatic brain injury, cerebral palsy, ...
(Date:3/22/2017)... ... 2017 , ... The Vanderbeck Agency, a Long Island firm providing insurance, financial ... on a combined charity effort with the Great Neck Breast Cancer Coalition to provide ... Great Neck Breast Cancer Coalition has worked to support breast cancer patients in the ...
(Date:3/22/2017)... ... , ... Chris Humphrey Insurance Agency, a North Carolina firm offering asset protection ... region, is initiating a charity event to raise support for five year old Dillyn, ... on a Friday evening in September 2014. At the time, Dillyn was only four ...
(Date:3/22/2017)... ... March 22, 2017 , ... HealthiPASS, ... providers while creating a positive patient experience. , HealthiPASS has further enhanced ... empowers patients by helping them understand their financial responsibility. “Our latest release ...
Breaking Medicine News(10 mins):